Reviews
15 September 2025
New papers
Advancements in transcatheter tricuspid valve repair and replacement: a state-of-the-art review with echocardiographic outcomes
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
0
Views
0
Downloads
Authors
Tricuspid regurgitation (TR) affects over 1.6 million individuals in the United States, with a one-year mortality rate of 36.1% and a five-year survival below 30%. Despite its prevalence being comparable to mitral regurgitation and aortic stenosis, TR remains understudied and inadequately managed. The underlying causes of TR vary, with primary TR stemming from structural abnormalities of the tricuspid valve, including damage caused by infectious endocarditis, rheumatic heart disease, congenital anomalies, or trauma, while secondary TR arises from right ventricular pressure and volume overload due to conditions such as heart failure (HF), atrial fibrillation, and pulmonary hypertension (PH). As TR progresses, it leads to higher hospitalization rates and imposes a significant healthcare burden, particularly in patients with advanced HF and PH. Medical therapy provides only symptomatic relief, while surgical intervention, carries high in-hospital mortality and complication risks. Given these challenges, transcatheter tricuspid valve interventions (TTVI) have emerged as promising alternatives, offering both transcatheter tricuspid valve repair (TTVr) and replacement (TTVR) strategies. TTVr devices such as TriClip, PASCAL, and Cardioband enhance leaflet coaptation or reduce annular dilation while preserving the native valve, resulting in lower procedural risks and faster recovery. Meanwhile, TTVR devices such as Evoque, TricValve, and LUX-Valve provide a definitive solution for patients with severe annular dilation, large coaptation gaps, or significant leaflet tethering. The growing population of underserved TR patients and the favourable outcomes of transcatheter therapies have accelerated advancements in device development and expanded treatment options. This review explores the latest advancements in TTVr and TVVR strategies, highlighting their clinical significance and echocardiographic outcomes based on recent data.
Graphical Abstract
Altmetrics
Downloads
Download data is not yet available.
Citations
1. Demir OM, Regazzoli D, Mangieri A, et al. Transcatheter tricuspid valve replacement: principles and design. Front Cardiovasc Med 2018;5:129.
2. Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol 2004;43:405-9.
3. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005-11.
4. Topilsky Y, Maltais S, Medina Inojosa J, et al. Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging 2019;12:433-42.
5. Obayashi Y, Kato T, Yaku H, et al. Tricuspid regurgitation in elderly patients with acute heart failure: insights from the KCHF registry. ESC Heart Fail 2023;10:1948-60.
6. Rahgozar K, Ho E, Goldberg Y, Chau M, Latib A. Transcatheter tricuspid valve repair and replacement: a landscape review of current techniques and devices for the treatment of tricuspid valve regurgitation. Expert Rev Cardiovasc Ther 2021;19:399-411.
7. Messika-Zeitoun D, Verta P, Gregson J, et al. Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis. Eur J Heart Fail 2020;22:1803-13.
8. Vidal-Pérez R, Jankowska EA. The scientific targets: the myocardium, the vasculature and the body’s response to heart failure. Global Cardiology 2024;2:19.
9. Albulushi A, Alfehaid LS, Alhussein M, Youssef A. Evaluating serum galectin-3 binding protein as a diagnostic and prognostic biomarker in pulmonary arterial hypertension: a comparative study. Global Cardiology 2024;2:50.
10. Alqahtani F, Berzingi CO, Aljohani S, Hijazi M, Al‐Hallak A, Alkhouli M. Contemporary trends in the use and outcomes of surgical treatment of tricuspid regurgitation. J Am Heart Assoc 2017;6:e007597.
11. Blusztein DI, Hahn RT. New therapeutic approach for tricuspid regurgitation: transcatheter tricuspid valve replacement or repair. Front Cardiovasc Med 2023;10:1080101.
12. Mulla S, Asuka E, Bora V, Sharma S, Siddiqui WJ. Tricuspid regurgitation. In: StatPearls [Internet]. StatPearls Publishing; 2024.
13. Frater R. Tricuspid insufficiency. J Thorac Cardiovasc Surg 2001;122:427-29.
14. Fioretti F, Lindman BR, Butler J. Biological plausibility and implications of obesity associated valvular heart diseases. Global Cardiology 2024;2:49.
15. Dietz MF, Prihadi EA, van der Bijl P, et al. Prognostic implications of right ventricular remodeling and function in patients with significant secondary tricuspid regurgitation. Circulation 2019; 140:836-45.
16. Wang TKM, Akyuz K, Mentias A, et al. Contemporary etiologies, outcomes, and novel risk score for isolated tricuspid regurgitation ACC Cardiovasc Imaging 2022; 15:731-44.
17. Goldberg YH, Ho E, Chau M, Latib A. Update on transcatheter tricuspid valve replacement therapies. Front Cardiovasc Med 2021;8:619558.
18. Taramasso M, Alessandrini H, Latib A, et al. Outcomes after current transcatheter tricuspid valve intervention: mid-term results from the international TriValve registry. JACC Cardiovasc Interv 2019;12:155-65.
19. Hoerbrand IA, Volz MJ, Aus dem Siepen F, et al. Initial experience with transcatheter tricuspid valve repair in patients with cardiac amyloidosis. ESC Heart Fail 2023;10:1003-12.
20. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561-632.
21. Muraru D, Hahn RT, Soliman OI et al. 3-dimensional echocardiography in imaging the tricuspid valve. JACC Cardiovasc Imaging 2019;12:500-15.
22. Kresoja KP, Rommel KP, Lücke C, et al. Right ventricular contraction patterns in patients undergoing transcatheter tricuspid valve repair for severe tricuspid regurgitation. JACC Cardiovasc Interv 2021;14:1551-61.
23. Ambrosino M, Sangoi M, Monzer N, et al. Tricuspid regurgitation: a review of current interventional management. J Am Heart Assoc 2024;13:e032999.
24. Lancellotti P, Pibarot P, Chambers J, et al. Multi-modality imaging assessment of native valvular regurgitation: an EACVI and ESC council of valvular heart disease position paper. Eur Heart J Cardiovasc Imaging 2022;23:e171-232.
25. Kaple RK, Agarwal V, Azarbal A et al. Tricuspid clip implantation using the MitraClip system-a step-by-step guide. Catheter Cardiovasc Interv 2021;98:1006-19.
26. Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet 2019;394:2002-11.
27. von Bardeleben RS, Lurz P, Sorajja P, et al. Two-year outcomes for tricuspid repair with a transcatheter edge-to-edge valve repair from the transatlantic TRILUMINATE trial. Circ Cardiovasc Interv 2023;16:e012888.
28. Lurz P, Rommel KP, Schmitz T, et al. Real-world 1-year results of tricuspid edge-to-edge repair from the BRIGHT Study. J Am Coll Cardiol 2024;84:607-16.
29. Nickenig G, Kowalski M, Hausleiter J, et al. Transcatheter treatment of severe tricuspid regurgitation with the edge-to-edge MitraClip technique. Circulation 2017;135:1802-14. Doi:
30. Russo G, Badano LP, Adamo M, et al. Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair-results from the TriValve registry. Eur J Heart Fail 2023;25:2243-51.
31. Kurnaz M, Ökçün S, Kahveci G et al. Cost-effectiveness analysis of the Triclip™ transcatheter tricuspid valve repair system in patients with tricuspid regurgitation. Anatol J Cardiol 2022;26:198-209.
32. Kodali S, Hahn RT, Eleid MF, et al. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol 2021;77:345-56.
33. Kodali SK, Hahn RT, Davidson CJ, et al. 1-Year outcomes of transcatheter tricuspid valve repair J Am Coll Cardiol 2023;81:1766-76.
34. Fam NP, Braun D, von Bardeleben RS, et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: A multicenter, observational, first-in-human experience. JACC Cardiovasc Interv 2019;12:2488-95.
35. Nickenig G, Weber M, Schueler R, et al. 6-Month outcomes of tricuspid valve reconstruction for patients with severe tricuspid regurgitation. J Am Coll Cardiol 2019;73:1905-15.
36. Nickenig G, Weber M, Schüler R, et al. Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study. EuroIntervention 2021;16:e1264-71.
37. Nickenig G, Friedrichs KP, Baldus S, et al. Thirty-day outcomes of the Cardioband tricuspid system for patients with symptomatic functional tricuspid regurgitation: The TriBAND study. EuroIntervention 2021;17:809-17.
38. Siminiak T, Dankowski R, Baszko A, et al. Percutaneous direct mitral annuloplasty using the Mitralign Bident system: description of the method and a case report. Kardiol Pol 2013;71:1287-92.
39. Hahn RT, Meduri CU, Davidson CJ, et al. Early feasibility study of a transcatheter tricuspid valve annuloplasty: SCOUT trial 30-day results. J Am Coll Cardiol 2017;69:1795-806.
40. Mangieri A, Lim S, Rogers JH, Latib A. Percutaneous tricuspid annuloplasty. Interv Cardiol Clin 2018;7:31-6.
41. ClinicalTrials.gov [Internet]. Identifier NCT02098200. Percutaneous treatment of tricuspid valve regurgitation with the TriCinch System™ (PREVENT). Accessed on: 2024 Aug 14. Available from: https://clinicaltrials.gov/study/NCT02098200
42. Rosser BA, Taramasso M, Maisano F. Transcatheter interventions for tricuspid regurgitation: TriCinch (4Tech). EuroIntervention 2016;12:Y110-2.
43. Latib A, Agricola E, Pozzoli A, et al. First-in-man implantation of a tricuspid annular remodeling device for functional tricuspid regurgitation. JACC Cardiovasc Interv 2015;8:e211-4.
44. Calen C, Taramasso M, Guidotti A, et al. Successful TriCinch-in-TriCinch transcatheter tricuspid valve repair. JACC Cardiovasc Interv 2017;10:e75-7.
45. Oliveira DC, Oliveira CGC. The forgotten, not studied or not valorized tricuspid valve: the transcatheter revolution is coming. Cardiol Res 2019;10:199-206.
46. Rogers JH, Boyd WD, Smith TWR, et al. Transcatheter annuloplasty for mitral regurgitation with an adjustable semi-rigid complete ring: initial experience with the millipede IRIS device. Structural Heart 2017; 2:43-50.
47. Puri R, Rodés-Cabau J. The FORMA repair system. Interv Cardiol Clin 2018;7:47-55.
48. Perlman GY, Dvir D. Treatment of tricuspid regurgitation with the FORMA repair system. Front Cardiovasc Med 2018;5:140.
49. Asmarats L, Perlman G, Praz F, et al. Long-term outcomes of the FORMA transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation: insights from the first-in-human experience. JACC Cardiovasc Interv 2019;12:1438-47.
50. Fam NP, von Bardeleben RS, Hensey M, et al. Transfemoral transcatheter tricuspid valve replacement with the EVOQUE system: A multicenter, observational, first-in-human experience. JACC Cardiovasc Interv 2021;14:501-11.
51. Webb JG, Chuang AM, Meier D, et al. Transcatheter tricuspid valve replacement with the EVOQUE system: 1-Year outcomes of a multicenter, first-in-human experience. JACC Cardiovasc Interv 2022;15:481-91.
52. Kodali S, Hahn RT, Makkar R, et al. Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study. Eur Heart J 2023;44:4862-73.
53. Grayburn PA, Kodali SK, Hahn RT, et al. TRISCEND II: Novel randomized trial design for transcatheter tricuspid valve replacement. Am J Cardiol 2024;225:171-7.
54. Sun Z, Li H, Zhang Z, et al. Twelve-month outcomes of the LuX-Valve for transcatheter treatment of severe tricuspid regurgitation. EuroIntervention 2021;17:818-26.
55. Mao Y, Li L, Liu Y, et al. Safety, efficacy, and clinical outcomes of transcatheter tricuspid valve replacement: one-year follow-up. Front Cardiovasc Med 2022;9:1019813.
56. Zhang Y, Lu F, Li W, et al. A first-in-human study of transjugular transcatheter tricuspid valve replacement with the LuX-Valve Plus system. EuroIntervention 2023;18:e1088-9.
57. Elgharably H, Harb SC, Kapadia S, et al Transcatheter innovations in tricuspid regurgitation: navigate. Prog Cardiovasc Dis 2019;62:493-5.
58. Hahn RT, Kodali S, Fam N, et al. Early multinational experience of transcatheter tricuspid valve replacement for treating severe tricuspid regurgitation. JACC Cardiovasc Interv 2020 13:2482-93.
59. Aoi S, Wiley J, Ho E, et al. Transcatheter tricuspid valve implantation with the Cardiovalve system. Future Cardiol 2021;17:963-9.
60. ClinicalTrials.gov [Internet]. Identifier NCT05486832. Safety and performance of the cardiovalve TR replacement system (TARGET). Accessed on: 2024 Aug 14. Available from: https://clinicaltrials.gov/study/NCT05486832
61. Maisano F, Hahn R, Sorajja P, et al. Transcatheter treatment of the tricuspid valve: current status and perspectives. Eur Heart J 2024;45:876-94.
62. Schmidt T, Kuck KH, Marquetand C, et al. CardioTwins: case report of a transcatheter mitral and tricuspid valve implantation in one patient. Eur Heart J Case Rep 2024;8:336.
63. Barreiro-Perez M, Estevez-Loureiro R, Baz JA, et al. Cardiovalve transfemoral tricuspid valve replacement assisted with CT-fluoroscopy fusion imaging. JACC Cardiovasc Interv 2022;15:e197-9.
64. Barreiro-Pérez M, González-Ferreiro R, Caneiro-Queija B, et al. Transcatheter tricuspid valve replacement: illustrative case reports and review of state-of-art. J Clin Med 2023;12:1371.
65. Zahr F, Song HK, Chadderdon SM, et al. 30-Day outcomes following transfemoral transseptal transcatheter mitral valve replacement: intrepid TMVR early feasibility study results. JACC Cardiovasc Interv 2022;15:80-9.
66. Bapat V. The INTREPID valve for severe tricuspid regurgitation: first-in-man case experience. Cardiovasc Res Technol 2020:22-5.
67. Lauten A, Dreger H, Schofer J, et al. Caval valve implantation for treatment of severe tricuspid regurgitation. J Am Coll Cardiol 2018;71:1183-4.
68. Loyalka P, Nascimbene A, Metz B, et al. Transcatheter tricuspid valve-in-valve replacement with an edwards sapien 3 valve. Tex Heart Inst J 2017;44:209-13.
69. Chandavimol M, Ngernsritrakul T, Meemook K, et al. Transcatheter tricuspid valve-in-valve implantation for degenerative surgical bio-prosthesis using SAPIEN 3: A case series. Clin Case Rep 2021;9:e05029.
70. Dreger H, Mattig I, Hewing B, et al. Treatment of severe TRIcuspid regurgitation in patients with advanced heart failure with CAval vein implantation of the edwards sapien XT VALve (TRICAVAL): a randomised controlled trial. EuroIntervention 2020;15:1506-13.
71. O’Neill BP, Wheatley G, Bashir R, et al. Study design and rationale of the heterotopic implantation of the edwards‐sapien XT transcatheter valve in the inferior VEna cava for the treatment of severe tricuspid regurgitation (HOVER) trial. Catheter Cardiovasc Interv 2016;88:287-93.
72. Blasco-Turrión S, Briedis K, Estévez-Loureiro R, et al. Bicaval TricValve implantation in patients with severe symptomatic tricuspid regurgitation: 1-year follow-up outcomes. JACC Cardiovasc Interv 2024;17:60-72.
73. Estévez-Loureiro R, Sánchez-Recalde A, Amat-Santos IJ, et al. 6-Month outcomes of the TricValve system in patients with tricuspid regurgitation: the TRICUS EURO study. JACC Cardiovasc Interv 2022;15:1366-77.
74. Di Mauro M, Guarracini S, Mazzocchetti L, et al. Transcatheter bicaval valve system for the treatment of severe isolated tricuspid regurgitation. features from a single-centre experience. Int J Cardiol 2024;402:131864.
75. Jin QW, Ghazi ABM, Kolanthaivelu J, Yahaya SA. Novel treatment of atrial functional tricuspid regurgitation using transcatheter bicaval valve implantation (TricValve). AsiaIntervention 2022;8:138-42.
76. Vaturi M, Vaknin-Assa H, Shapira Y, et al. First-in-human percutaneous transcatheter tricuspid valve replacement with a novel valve. JACC Case Rep. 2021;3:1281-6.
77. Montorfano M, Beneduce A, Ancona MB, et al. Tricento transcatheter heart valve for severe tricuspid regurgitation: procedural planning and technical aspects. JACC Cardiovasc Interv 2019;12:e189-91.
78. Wild MG, Lubos E, Cruz-Gonzalez I, et al. Early clinical experience with the TRICENTO bicaval valved stent for treatment of symptomatic severe tricuspid regurgitation: a multicenter registry. Circ Cardiovasc Interv 2022;15:e011302.
79. Teiger E, Nejjari M, Lim P, et al. First-in-human implantation of the topaz transcatheter tricuspid valve replacement system. EuroIntervention 2022;18:862-4.
80. CroiValve. Positive six-month results from CroíValve’s TANDEM I study to treat tricuspid regurgitation presented at New York Valves 2024 [Internet]. CroíValve; 2024. Available from: https://www.croivalve.com/positive-six-month-results-from-croivalves-tandem-i-study-to-treat-tricuspid-regurgitation-presented-at-new-york-valves-2024/
81. ClinicalTrials.gov [Internet]. Identifier NCT05848284. Clinical safety and efficacy of the VDyne transcatheter tricuspid valve replacement system for the treatment of tricuspid regurgitation (VISTA-US). Accessed on: 2024 Aug 14.Available from: https://clinicaltrials.gov/study/NCT05848284
82. Jensen RV, Jensen JK, Christiansen EH, et al. Two case reports of transcatheter valve-in-valve implantation of sapien 3 and MyVal in degenerated biological tricuspid prosthesis valves. Eur Heart J Case Rep 2022;6:ytac131.
83. Waggoner TE. Early feasibility study of Laplace TTVR system in patients with severe, symptomatic tricuspid regurgitation. Available from: https://www.tctmd.com/slide/early-feasibility-study-laplace-ttvr-system-patients-severe-symptomatic-tricuspid
84. Ussia GP, Mangieri A, Cammalleri V, et al. 6 Months' follow-up of the first-in-man implantation of a novel tricuspid flow optimizer. JACC Cardiovasc Interv 2024;17:1500-1.
85. Ussia GP. Percutaneous treatment of tricuspid regurgitation with the novel TriFlo device: first-in-human Italian experience. Available from: https://www.tctmd.com/slide/percutaneous-treatment-tricuspid-regurgitation-novel-triflor-device-first-human-italian
86. Saini A, Kim DW, Maher KO, Deshpande SR. Melody valve implantation in the tricuspid position after pediatric heart transplantation-a case report. J Soc Cardiovasc Angiogr Interv 2024;3:101354.
87. Duarte D, Prieto LR, Suntharos P. Melody valve-in-valve implantation in the tricuspid position through a fontan conduit fenestration. Ann Pediatr Cardiol 2022;15:180-2.
88. Planer D, Beeri R, Danenberg HD. First-in-human transcatheter tricuspid valve repair: 30-day follow-up experience with the mistral device. JACC Cardiovasc Interv 2020;13:2091-6.
89. Reddy VY, Abbo AR, Ruiz CE, et al. First-in-human percutaneous circumferential annuloplasty for secondary tricuspid regurgitation. JACC Case Rep 2020;2:2176-82.
90. ClinicalTrials.gov [Internet]. Identifier NCT03700918. A first in human study to assess safety and performance of the Davingi™ TR system in the treatment of patients with functional tricuspid regurgitation. Accessed on: 2024 Aug 14. Available from: https://clinicaltrials.gov/ct2/show/NCT03700918
91. Rogers T, Ratnayaka K, Sonmez M, et al. Transatrial intrapericardial tricuspid annuloplasty. JACC Cardiovasc Interv 2015; 8:483-91.
92. Khan JM, Rogers T, Schenke WH, et al. Transcatheter pledget-assisted suture tricuspid annuloplasty (PASTA) to create a double-orifice valve. Catheter Cardiovasc Interv 2018;92:E175-84.
93. Greenbaum AB, Khan JM, Rogers T, et al. First-in-human transcatheter pledget-assisted suture tricuspid annuloplasty for severe tricuspid insufficiency. Catheter Cardiovasc Interv 2021;97 E130-4.
94. Hennemann W. STTAR: The study of transcatheter tricuspid annular repair. Presented at: PCR e-course; 2020.
95. Pan W, Long Y, Zhang X, et al. Feasibility study of a novel transcatheter tricuspid annuloplasty system in a porcine model. JACC Basic Transl Sci 2022;7:600-7.
96. Xu H, Li W, Lee AP, et al. 30-Day outcomes of transcatheter tricuspid annuloplasty with the k-clip system: a single-center, observational study. JACC Adv 2023; 2:100671.
97. Alfieri O, De Bonis M, Lapenna E, et al. The "clover technique" as a novel approach for correction of post-traumatic tricuspid regurgitation. J Thorac Cardiovasc Surg 2003;126:75-9.
98. Fam NP. Return of the tricuspid spacer: filling an unmet clinical need. JACC Basic Transl Sci 2022;7:1262-3.
99. Dahou A, Levin D, Reisman M, Hahn RT. Anatomy and physiology of the tricuspid valve. JACC Cardiovasc Imaging 2019;12:458-68.
100. Jang JY, Heo R, Lee S, et al. Comparison of results of tricuspid valve repair versus replacement for severe functional tricuspid regurgitation. Am J Cardiol 2017;119:905-10.
How to Cite
1.
Rao AG, Javaid SS, Rashid AM, Alenezi F. Advancements in transcatheter tricuspid valve repair and replacement: a state-of-the-art review with echocardiographic outcomes. Global Cardiol [Internet]. 2025 Sep. 15 [cited 2025 Sep. 15];. Available from: https://www.globalcardiology.info/site/article/view/81
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
